ARIBIOLAB
Founded in 2000 and KOSDAQ-listed in 2021, AribioLAB develops next-generation vaccines using its L-pampo® and Lipo-pam® adjuvant platforms.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2021, AribioLAB is a biotech venture that joined the Cha Bio Group in 2011 when Cha Bio&Diostech became its largest shareholder. Built on its proprietary adjuvant platforms L-pampo® and Lipo-pam®, the company develops next-generation vaccines and immunotherapeutics including a chronic hepatitis B therapeutic vaccine, a hepatitis B preventive vaccine, and a recombinant herpes zoster vaccine. L-pampo® shows more than 100-fold higher antibody formation than the conventional adjuvant alum, and the company holds an S-grade patent, the highest of nine grades under the KEV patent evaluation rating system.
Products & technology
- L-pampo®TLR2/TLR3 ligand complex adjuvant that enhances immune response to vaccine antigens
- Lipo-pam®Liposomal adjuvant combining immune enhancement and antigen delivery, applied to therapeutic vaccine development
Clinical trials
data.go.kr6 MFDS clinical trial authorisations · 2012–2025 (Phase 1 2 · Phase 1/2a 2 · Phase 2 1 · Phase 2b 1)
- Phase 2CVI-VZV-0012025-12-18
7 trial sites
- Phase 1CVI-VZV-0012022-12-05
2 trial sites
- Phase 1CVI-HBV-0022021-06-02
1 trial site
- Phase 2bCVI-HBV-0022019-10-07
9 trial sites
- Phase 1/2aCVI-HBV-0022014-05-26
2 trial sites
- Phase 1/2aCVI-HBV-0012012-08-02
1 trial site
R&D and key agreements
Source: DART corporate disclosure만성 B형간염 치료백신 · 만성 B형간염 · Lead pipeline developed alongside an improved prophylactic vaccine
B형간염 예방백신 · B형간염 · Prophylactic vaccine under development with improved efficacy versus existing vaccines
재조합 대상포진 백신 · 대상포진 · One of the company lead pipeline products
노인용 독감 백신 · 인플루엔자 · Pipeline improving efficacy of existing influenza vaccines for the elderly
노로바이러스 백신 · 노로바이러스 감염증 · Development of a previously non-commercializable norovirus vaccine
항암백신 · 암 · Pipeline aimed at preventing cancer recurrence and maximizing efficacy via combination therapy
Key disclosures
KRX KIND via OpenDARTShow 1 more events
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot27
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ARIBIOLAB and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition